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HEART FAILURE
Heart failure (HF) is a global health problem that af-
fects about 40 million people worldwide (1). Approxi-
mately 2% of adults have HF and in those over the age 
of 65, it increases to 6%-10% (2). Above 75 years of 
age, the rates are greater than 10% (3). Unfortunately, 
morbidity rate is predicted to increase because of the 
increased life span and risk factors such as hyperten-
sion, diabetes, dyslipidemia, and obesity (4). HF is the 
leading cause of hospitalization in people older than 
65. 
Th e main terminology used to describe HF is histori-
cal and based on measurement of the left  ventricular 
ejection fraction (LVEF). HF comprises a wide range 
of patients, from those with normal LVEF [typically 
considered as ≥50%; HF with preserved EF (HFpEF)] 
to those with reduced LVEF [typically considered as 
40%; HF with reduced EF (HFrEF)]. Patients with an 
LVEF in the range of 40%-49% represent a ‘grey area’, 
which the European Society of Cardiology (ESC) now 
defi nes as HFmrEF. Diff erentiation of patients with 
HF based on LVEF is important due to diff erent un-
derlying etiologies, demographics, comorbidities and 
response to therapies (5).
EXTRACELLULAR MATRIX ABNORMAL 
CHANGES IN HEART FAILURE
Extracellular matrix (ECM) includes a network of 
fi brillar collagen, basement membrane and proteo-
glycans. Fibrillar collagens (collagen type I and type 
III) ensure structural integrity of the boundary cells, 
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thus ensuring structural stability. ECM is a dynamic, 
metabolically active structure that plays an indepen-
dent and important role in the progression of multiple 
vascular diseases. Increased accumulation of fi brillar 
collagen, or fi brosis, has been observed in various 
pathological conditions. Heart failure is a well-known 
example of such an adverse accumulation of ECM, 
raising myocardial stiff ness and impairing heart con-
tractile behavior. According to the current knowledge, 
the most certain collagen type I and III turnover bio-
markers with clinical and laboratory value are the fol-
lowing four: N-terminal propeptide of collagen type 
I (PINP), N- terminal propeptide of collagen type III 
(PIIINP), C-terminal propeptide of collagen type I 
(PICP) and C-terminal telopeptide of collagen type I 
(ICTP). All of them are collagen-derived peptides as 
PINP and PICP refl ect collagen type I synthesis, PII-
INP refl ects collagen type III synthesis, while ICTP 
shows collagen type I degradation. 
It is well known that some cardiovascular diseases such 
as hypertension, coronary artery disease, valvular dis-
ease, and arrhythmias oft en progresses to HF. An asso-
ciation between cardiac remodeling and development 
of HF has been estimated (6). Cardiac remodeling is 
defi ned as a group of molecular, cellular and intersti-
tial changes that manifest clinically as alterations in 
the size, mass, geometry and function of the heart af-
ter a stressful stimulus. Th is process can be triggered 
by ischemia (myocardial infarction) (7,8), infl amma-
tion (myocarditis), hemodynamic overload (workload 
by volume or pressure) (9) and neurohormonal acti-
vation (10,11). Cardiac remodeling is considered to be 
not only an adaptive event but also a maladaptive pro-
cess. In result, at fi rst stage cellular changes occur in 
heart structure such as myocyte hypertrophy, necro-
sis, apoptosis, followed by second stage of an increased 
ECM deposition of fi brillar collagen, oft en described 
by the term ‘myocardial fi brosis’. It is associated with 
accelerated collagen metabolism and impaired synthe-
sis and accumulation mainly of collagen type I and III 
in myocardium (12-18). In later stages of remodeling, 
heart function is inevitably impaired.
COLLAGEN TYPE I CHARACTERISTICS
Type I collagen is a fi brillar collagen and а major part 
of the interstitial membrane structure. It is the most 
prevalent type of collagen and a key structural com-
position of many tissues. It is found practically in all 
structures involving connective tissue. Type I collagen 
is the main structural protein of bone, skin, tendon, 
ligaments, sclera, cornea, blood vessels, as well as an 
important component of other tissues. It is collected in 
fi bers forming structural-mechanical scaff old (matrix) 
of bones, skin, tendons, cornea, blood vessel walls, and 
other connective tissues. Heterotrimers of two α1 (I) 
and one α2 (I) chains are the dominant isoform of type I 
collagen. Homotrimers of three α1 (I) chains are found 
in fetal tissues and some fi brous lesions (19). Th e ho-
motrimeric isoform is more resistant to cleavage than 
collagenases, which may explain its accumulation and 
functional role in tumors and fi brotic lesions (Fig. 1).
Fig. 1. Collagen type I structure
PICP = collagen-derived peptide including the carboxy-terminal peptide 
of procollagen type I formed on extracellular conversion of procollagen 
type I into fi brillar collagen I; PINP = collagen-derived peptide including 
the amino-terminal propeptide of collagen type I; ICTP = telopeptide of 
collagen type I. Adapted from Gao L, Orth P, Cucchiarini, M, Madry H. 
Eff ects of solid acellular type-I/III collagen biomaterials on in vitro and 
in vivo chondrogenesis of mesenchimal stem cells. Exp Rev Med Devices 
2017; 14(9):717-32.
COLLAGEN TYPE III CHARACTERISTICS
Type III collagen is composed of one collagen α-chain, 
unlike most other collagens. It is a homotrimer con-
taining three α1 (III) chains overlapped in a right triple 
helix. Type III collagen is secreted by fi broblasts and 
other types of mesenchymal cells, thus playing a major 
role in diff erent infl ammatory pathological conditions 
such as lung damage, liver diseases, renal fi brosis, and 
vascular fi brosis. Both collagen type III and type I are 
the main components of the ECM (20). Type III colla-
gen immunological biomarkers have been developed 
and widely used for detection of fi brosis (Fig. 2).
Fig. 2. Collagen type III structure
PIIINP = collagen-derived peptide including the amino-terminal propep-
tide of collagen type III arising on extracellular conversion of procollagen 
III to fi brillar collagen III to fi brillar collagen III. Adapted from Gao L, 
Orth P, Cucchiarini M, Madry H. Eff ects of solid acellular type-I/III colla-
gen biomaterials on in vitro and in vivo chondrogenesis of mesenchimal 
stem cdells. Exp Rev Med Devices 2017; 14(9) 717-32.
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CARDIAC FIBROSIS
Extracellular matrix is composed of fi brillar collagen 
types I and III, fi bronectin, laminin, fi brillin, elastin, 
glycoproteins and proteoglycans; cardiac fi broblasts 
are the primary source of these ECM proteins. Car-
diac fi broblasts also produce matrix metalloprotein-
ases (MMPs), as well as tissue inhibitors of MMPs 
(TIMPs), which are ECM-regulatory proteins. MMPs 
are proteases that degrade ECM proteins and TIMPs 
can inhibit MMP function; their balanced equilibrium 
is critical for ECM homeostasis. 
Cardiac ECM is composed predominantly of collagen 
type I (85%) and III (11%). Collagen type I and III are 
synthesized by cardiac fi broblasts. Th ey are the main 
collagen-producing cells in the heart. Fibrillar colla-
gen is synthesized fi rstly as a procollagen, which is 
split by specifi c proteinases in carboxy (C)- and amino 
(N)-terminal propeptides.
Th e N-terminal propeptides of collagen type I or III 
(PINP and PIIINP) and the C-terminal propeptides 
(PICP and PIIICP) are used as markers of collagen 
type I or III synthesis. Aft er splitting of the propep-
tides, the triple helix chain will form big collagen fi -
bers with other collagen chains. During degradation 
of these collagen fi bers by collagenases (MMP-1, -8, 
-13), telopeptides are formed. Th e big telopeptide un-
dergoes spontaneous denaturation in nonhelical de-
rivatives, which are completely degraded into inactive 
fragments by interstitial gelatinases (MMP-2, -9). Th e 
small telopeptide of collagen type I (ICTP, 12 kDa) 
can be used as a marker of collagen type I degradation 
(21).
Accumulation of fi brillar collagen, or fi brosis, is inten-
sifi ed in heart failure. Early studies in the fi eld of con-
gestive heart failure (CHF) clearly demonstrate that 
extracellular degradation enzymes (MMPs) are found 
in the myocardium of patients with CHF (22). Eval-
uation of cardiac collagen metabolism by biological 
markers is a useful tool for monitoring cardiac tissue 
remodeling and fi brosis, both in laboratory models 
and in clinical studies (23). Along with increasing lev-
els of collagen synthesis markers, the results reported 
from some studies suggest that collagen degradation is 
slower in patients with CHF, leading to cardiac fi brosis 
(19,20). 
Fibrosis is a response of hyperactivity of cardiac fi -
broblasts that occurs in response to certain stressful 
stimuli. As a result, recruitment and proliferation of 
circulating bone marrow-derived cells infi ltrate the 
myocardium and transform into cardiac fi broblasts. It 
has been reported in some studies that increased lev-
els of collagen synthesis biomarkers (PICP, PINP, PII-
INCP, PIIINP) and reduced serum levels of collagen 
type I degradation biomarker (CITP) lead to collagen 
deposition and fi brosis (24-26). Th ese data show that 
the balance between cardiac collagen synthesis and 
degradation is disturbed in pathogenic conditions 
(22,23). Patients with heart failure are an example of 
impaired collagen turnover (27,28).
CIRCULATING SERUM COLLAGEN 
BIOMARKERS AND HEART FAILURE 
Several studies have been performed on collagen type 
I and III metabolism so far. Th ey show that their turn-
over is mainly regulated by N-terminal propeptide 
of collagen type I (PINP), N- terminal propeptide of 
collagen type III (PIIINP), C- terminal propeptide of 
collagen type I (PICP) and C-terminal telopeptide of 
collagen type I (ICTP). Th ey are collagen-derived pep-
tides as PINP and PICP show collagen type I synthesis, 
PIIINP refl ects collagen type III synthesis, while ICTP 
marks collagen type I degradation (25,26).
N-terminal propeptide of collagen type III (PIIINP)
PIIINP is a marker of collagen type III synthesis. Most 
serum PIIINP is generated during the extracellular 
conversion of procollagen type III to collagen type III 
by the enzyme procollagen aminoterminal protein-
ase (29). Serum PIIINP concentration correlates with 
the myocardial area fractions of their tissue analogs. 
Th e increase in ECM turnover, which may partially 
be derived from fi brosis in the myocardium, can be 
measured in the serum of patients with dilated cardio-
myopathy, and has an impact on risk stratifi cation and 
prognosis (30). In addition, reduction in the extent of 
collagen volume fraction in HF patients treated with 
spironolactone is accompanied by reductions in se-
rum PIIINP (31) Serum PIIINP is associated with the 
severity (43) and outcomes of HF of diff erent causes 
regardless of EF (32,33).
PIIINP levels are elevated in all HF patients regard-
less of EF. Th ere is a decreased survival rate in patients 
with HFrEF, but the cutoff  point is diff erent, i.e. ac-
cording to Zannad et al. (33) PIIINP >3.85 μg/L, in 
comparison with data of Klappacher et al. (30) PIIINP 
>7 μg/L, with clarifi cation that patients in the latter 
study were all with dilated cardiomyopathy (33 idio-
pathic and 8 ischemic cases). Patients with HF, dilat-
ed and hypertrophic cardiomyopathy (DCM, HCM) 
have signifi cantly higher serum PIIINP levels than 
healthy control subjects. Hypertensive patients with 
HFpEF also have signifi cantly higher serum PIIINP 
concentrations than hypertensive patients with HFrEF 
and HFmrEF (31). Th e survival rate decreases if the 
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patient with HF (33,35) or with DCM (36) has an 
elevated PIIINP level. Th e serum PIIINP concentra-
tion is also signifi cantly higher in patients with acute 
myocardial infarction and PIIINP >5 μg/L is an inde-
pendent predictor of cardiac death and in-hospital de-
velopment of CHF (37). Th ere is only one study with 
patients with HFmrEF (32) which reports a decreased 
survival if PIIINP >4.7 μg/L (Table 1).
Table 1. 
Serum levels of PIIINP in patients with heart failure
Author Heart failure type Main fi ndings 
Alla et al. (23) HFrEF Increased PIIINP levels
Barasch et al. (57) HFrEF vs. HFpEF Associated with HFpEF
Cicoira et al. (35) HFmrEF
Decreased survival if PIIINP 
>4.7 μg/L
Martos et al. (34) HFpEF Increased PIIINP levels
Plaksej et al. (50) HF
Increased levels in NYHA III + 
IV class
Zannad et al. (33) HFrEF
Decreased survival if PIIINP 
>3.85 μg/L
Zile et al. (64) HF Increased PIIINP levels
Klappacher et al. (30) DCM
Decreased survival if PIIINP >7 
μg/L
Host et al. (37) HF Increased PIIINP levels
Schwartzkopff et al.(65) HF
Independent predictors of 
mortality
Michalski et al. (67) HFrEF vs. HFpEF
PIIINP showed strong negative 
correlation with LV-strains
MESA (Multi-Ethnic Study 
of Atherosclerosis) (67)
HF Increased PIIINP levels
NYHA = New York Heart Association; DCM = dilated cardiomyopathy; 
HF = heart failure not defi ned by left  ventricular ejection fraction (LVEF); 
HFrEF = heart failure with reduced ejection fraction (LVEF <40%); 
HFmrEF = heart failure with mid-range ejection fraction (LVEF 40%-
49%); HFpEF = heart failure with preserved ejection fraction; (LVEF 
≥50%)
N-terminal propeptide of collagen type I (PINP)
PINP is a marker of collagen type I synthesis. Procolla-
gen type I propeptides are derived from collagen type 
I. Th is precursor contains a short signal sequence and 
terminal extension peptides, amino-terminal propep-
tide (PINP) and carboxy-terminal propeptide (PICP). 
Th ese propeptide extensions are removed by specifi c 
proteinases before the collagen molecules form. Both 
propeptides can be found in the circulation and their 
concentration refl ects the synthesis rate of collagen 
type I (38,39). In comparison with control subjects, 
PINP is not signifi cantly diff erent in patients with 
HCM (40), HF (41) and in hypertensive patients with 
or without diastolic HF (34). 
C-terminal propeptide of collagen type I (PICP)
PICP is a marker of collagen type I synthesis. Serum 
carboxy-terminal propeptide of procollagen type I 
(PICP) is generated during the extracellular conversion 
of procollagen type I into collagen type I by the enzyme 
bone morphogenetic protein-1 or procollagen car-
boxy-terminal proteinase (42). A net release from heart 
into the circulation has been reported in HF (43), sug-
gesting a cardiac origin of systemic PICP. Serum PICP 
concentrations correlate with collagen volume fraction 
(43-45) in HF. Results reported by of Lopez et al. (45) 
show that PICP levels decrease in patients with hyper-
tensive heart failure with torasemide treatment. Serum 
PICP is associated with HFrEF severity (46), and with 
mortality in HFpEF (47) and HFrEF (48). Of interest, 
the serum PICP-to-serum PIIINP ratio is related to 
malignant ventricular arrhythmogenesis in HF (49). 
Data show that PICP levels are signifi cantly increased 
in more studies with patients with HFpEF than HFrEF. 
Higher serum PICP level is found in patients with HF 
compared to control subjects, except for the studies 
by Alla et al. (22) and Plaksej et al. (50). Serum PICP, 
as well as coronary PICP, is positively correlated with 
the myocardial collagen content (51,52). Th ere is no 
diff erence in serum PICP levels in patients with HCM 
(53) and DCM (54) as compared to controls. Th ere is 
only one study including patients with HFmrEF, which 
shows that an excess of cardiac collagen type I synthesis 
and deposition may be involved in the enhancement of 
myocardial fi brosis that accompanies development of 
HF in hypertensive heart disease (43) (Table 2).
Table 2. 
Serum levels of PICP in patients with heart failure
Author Heart failure type Main fi ndings
Gonzalez et al. (45) HFpEF
Increased PICP levels in both 
groups, patients with NYHA 
class II to IV CHF treated with 
torasemide vs. furosemide
Querejeta et al. (43) HFmrEF Increased PICP levels
Plaksej et al. (50) HF Non signifi cant difference
Lopez et al. (51) HHD
Strong correlation between 
myocardial collagen content and 
serum concentration of PICP 
Martos et al. (34) HFpEF Increased PICP levels 
Barasch et al. (57) HF Associated with HFpEF
Alla et al. (23) HFrEF Nonsignifi cant difference
Schwartzkopff et al.(65) HFmrEF Nonsignifi cant difference
NYHA = New York Heart Association; HHD = hypertensive heart di-
sease; HF = heart failure not defi ned by left  ventricular ejection fracti-
on (LVEF); HFrEF = heart failure with reduced ejection fraction (LVEF 
<40%); HFmrEF = heart failure with mid-range ejection fraction (LVEF 
40%-49%); HFpEF = heart failure with preserved ejection fraction; 
(LVEF ≥50%)
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C-terminal telopeptide of collagen type I (ICTP)
ICTP is a marker of collagen type I degradation. Data 
show that ICTP levels are elevated in both groups, 
HFrEF and HFpEF. Increased ICTP serum levels are 
observed in patients with DCM and HCM too. Serum 
ICTP is positively related with collagen content in the 
myocardium (30) and it is a predictor of mortality if 
>7.6 μg/L (55). In hypertensive patients with HF, se-
rum ICTP level is increased in NYHA class IV (50). 
Barasch et al. (56) did not fi nd an association between 
ICTP and HFrEF and HFpEF. In patients with acute 
myocardial infarction, Manhenke et al. (57) demon-
strated that ICTP was an independent predictor of to-
tal and cardiovascular mortality.
Serum collagen type I telopeptide-to-serum matrix 
metalloproteinase-1 ratio is a novel candidate marker 
studied in the last two years. As collagen cross-linking 
determines collagen fi ber resistance to MMP degra-
dation, the higher the cross-linking of collagen type 
I fi bers, the lower is the cleavage of the peptide colla-
gen type I telopeptide (CITP) by the enzyme MMP-1. 
Th us, the serum CITP-to-serum MMP-1 ratio is in-
versely correlated with myocardial collagen cross-link-
ing (58). Th e CITP-to-MMP-1 ratio is independently 
associated with the risk of HF hospitalization (58). Th e 
combination of low CITP-to-MMP-1 ratio and high 
PICP identifi es HF patients with the highest risk (59) 
(Table 3).
Table 3. 
Serum levels of ICTP in patients with heart failure
Author Heart failure type Main fi ndings
Plaksej et al. (50) HF Increased ICTP levels in NYHA IV 
Kitahara et al. (55) HFpEF
Event-free point decreases when 
ICTP >7.3 ng/mL
Barasch et al. (57) HF
Not associated with HFpEF or 
HFrEF
Zile et al. (64) HFpEF Increased ICTP levels
Klappacher et al. (30) DCM
Increased mortality if ICTP >7.6 
μg/L
Schwartzkopff et al. (65) HFmrEF Increased ICTP levels
Batlle et al. (68) HF
Increased ICTP levels and 
increased risk of clinical event
MESA (Multi-Ethnic Study 
of Atherosclerosis) (67)
HF High levels of circulating ICTP 
NYHA = New York Heart Association; DCM = dilated cardiomyopathy; 
HF = heart failure not defi ned by left  ventricular ejection fraction (LVEF); 
HFrEF = heart failure with reduced ejection fraction (LVEF <40%); 
HFmrEF = heart failure with mid-range ejection fraction (LVEF 40%-
49%); HFpEF = heart failure with preserved ejection fraction; (LVEF 
≥50%)
CONCLUSIONS AND PERSPECTIVES
Alteration of ECM structure and function may be the 
key in revealing the mechanism of cardiac remodel-
ing. Impairment of the ECM network integrity disor-
ganizes and interrupts connections between myocar-
dial cells and blood vessels. Th is could later lead to 
shift ing of heart function. Fibrosis and overproduc-
tion of ECM proteins result in enhanced stiff ness of 
the myocardium wall, followed by systolic and diastol-
ic dysfunction. 
Th e use of serum collagen-derived peptides (PINP, 
PICP, PIIINP and ICTP) for collagen type I and III 
turnover in heart failure is very promising. Poten-
tial routine clinical applications of serologic markers 
of collagen metabolism can hopefully be introduced 
soon. Despite this fact, there are some controversial 
fi ndings and limitations in the studies commented 
here. Some important critical remarks make gaps in 
evidence. Th at is why the following questions con-
cerning PINP, PICP, PIIINP and ICTP as indicators 
for diagnosis, prognosis and development of heart 
failure should to be taken into account:
• Changes in collagen turnover are likely to occur 
at a very early stage of heart failure, even before 
disease is clinically diagnosed. Can collagen bio-
markers be used to predict development and 
prognosis of heart failure?
• Whether collagen metabolism markers give 
enough information as lone indicators, or do we 
need a combination model adding other cardio-
vascular markers, for example creatine phosphoki-
nase, troponin? Furthermore, is it more appropri-
ate to use an integrative model using combination 
of serum markers and image test than using just 
one of them for diagnosis, prognosis and monitor-
ing of heart failure?
• Analyzing the above mentioned studies, some dif-
ferences can be noted between the cutoff  points 
for detection of serum levels of collagen turnover 
markers in HF according to the EF. 
• In hypertensive patients with heart failure, se-
rum collagen type I telopeptide-to-serum matrix 
metalloproteinase-1 ratio (ICTP/MMP-1) is in-
dependently associated with the risk of HF hospi-
talization (58). Th e combination of low CITP-to-
MMP-1 ratio and high PICP identify HF patients 
with the highest risk than ICTP alone (59). Not only 
their absolute serum levels, but also the relationship 
between their serum concentration ratios could 
play a role in myocardial remodeling in HF. Prob-
ably the ratios between collagen marker and MMP 
are a more accurate indicator than a marker alone. 
• Th e underlying factor causing the heart failure 
syndrome aff ects collagen biomarker turnover in 
diff erent ways. For example, hypertension is ac-
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companied by hypertrophy of cardiac myocytes 
and increased stiff ness of the ventricle wall, which 
suggests an increase in collagen fi bers. Patients 
with hypertension have thus an increase in bio-
markers of the synthesis of collagen, such as PII-
INP and PICP. 
• Diff erent characteristics of HF patients such as HF 
treatment, comorbidities, age and body mass index 
can infl uence the levels of collagen biomarkers. 
• Cardiac remodeling is a continuous process, while 
most studies were cross-sectional and report the 
levels of biomarkers only at one certain time point. 
Th ese biomarkers should, however, be determined at 
various time points of the remodeling process. Th ere 
is a need for larger and longitudinal investigations.
• Is a serum biomarker representative of the tissue 
level? A method to correlate serum levels of the bio-
markers with cardiac remodeling is immunohisto-
chemistry and histology of cardiac biopsies, which 
cannot be performed in cross-sectional studies. In 
some studies, the association between serum bio-
markers and collagen content in the myocardium 
was investigated and serum PICP concentration 
was directly correlated with the fi brillar collagen 
fraction of the myocardium (43,52), which suggests 
that PICP is representative for cardiac collagen. 
PIIINP is also correlated with collagen type III and 
collagen type I, which makes PIIINP less represen-
tative for collagen type III synthesis alone (32). 
• Th e propeptides can be incorporated in the net-
work of collagen fi bers and not cleaved off  and 
eliminated in the circulation. At this point, PINP 
and PIINP underestimate partially collagen syn-
thesis. Th e elimination of the peptides occurs 
through various pathways and is a variable pro-
cess, which can aff ect the concentration of the bio-
markers (60,61).
• Testing for circulating biomarkers of myocardi-
al interstitial fi brosis presents several limitations. 
Th ey are not thoroughly cardiac-specifi c, and 
changes in their concentrations may represent in-
tegrated abnormalities of the cardiovascular col-
lagen and/or infl uence of comorbidities aff ecting 
collagen metabolism. Fibrosis also occurs in other 
organs and it is possible that increased levels of 
these biomarkers come not only from cardiac or-
igin but also from other diseased organs such as 
bone, liver, kidneys and lungs. Th at is why in all 
reported studies osteoporosis, renal failure and he-
patic fi brosis were used as exclusion criteria (62).
• In most of the studies, patients were obviously 
treated with standard HF pharmacotherapy. How-
ever, does the drug treatment aff ect the elimina-
tion of these propeptides by liver and kidneys and 
does it interfere with the dynamic processes in 
cardiac extracellular matrix? 
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Ekstracelularni matriks srca je složena struktura koja se prikazuje kao mreža vlaknatog kolagena, fi bronektina, laminina, 
fi brilina, elastina, glikoproteina i proteoglikana. Vlaknati kolageni miokarda (kolagen tipa I. i tipa III.) su glavni proteini o 
kojima ovisi strukturni integritet graničnih kardiomiocita. Povećano nakupljanje vlaknatih kolagena koje dovodi do fi bro-
ze opisano je u patološkim kardiovaskularnim stanjima kao što je zatajenje srca. Amino-terminalni i karboksi-terminalni 
propeptidi kolagena tipa I. i III. dva su glavna tipa kolagena koji imaju središnju ulogu u tom procesu. Produkti njihove 
pretvorbe određivani su u serumu bolesnika sa zatajenjem srca. Propetidi kolagena tipa I. i III. odražavaju sintezu i raspad 
kolagena. Njihova upotreba kao biomarkera područje je intenzivnih studija sa svrhom prognoze ili dijagnoze. Ovaj pregledni 
rad sažima danas raspoložive podatke iz literature o biljezima pretvorbe kolagena tipa I. i III. kod zatajenja srca i raspravlja 
se o njihovom potencijalu kao cirkulirajućim pokazateljima fi broze srca. Raspravlja se i o primjeni peptida kolagena tipa I. i 
III. za dijagnozu, prognozu i praćenje zatajenja srca.
Ključne riječi: kolagen, biomarkeri, zatajenje srca, fi broza miokarda
S A Ž E T A K
SERUMSKI BIOMARKERI PRETVORBE KOLAGENA I I III. KOD ZATAJENJA SRCA – POTREBA 
PONOVNE PROCJENE
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